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Introduction {#sec005}
============

Staghorn stones still represent an intractable challenge to urologists. Open surgery (OS) was once considered to be the "gold standard" for the surgical treatment of staghorn calculi. However, thanks to miniaturization of endoscopic devices, increasing quality of optic systems, advent of holmium laser use and increasing experience in endoscopic surgery, the surgical management of staghorn calculi has been revolutionized. And the American Urological Association(AUA) guidelines for the management of staghorn calculi recommend percutaneous nephrolithotomy (PCNL) as the modality of choice and standard of practice\[[@pone.0206810.ref001]\].

However, not only the stone burden but also the morphology of stones can significantly affect the outcomes of PCNL in the management of staghorn calculi\[[@pone.0206810.ref002],[@pone.0206810.ref003]\]. This is in contrast to OS, which is little affected by the morphometric index of staghorn calculi. Due to some reasons such as the unavailability of surgical instruments, higher stone free rate(SFR) or shorter operative times, many urologists still recommend OS for patients with complex staghorn calculi\[[@pone.0206810.ref004]--[@pone.0206810.ref006]\].

Some previous studies\[[@pone.0206810.ref006]--[@pone.0206810.ref015]\] had compared PCNL versus OS. Nevertheless, all these studies were small samples, and the results were controversial and inconclusive. The optimal treatment for staghorn calculi is still under debate. No meta-analysis has investigated the efficacy and safety of those two procedures. And whether PCNL is safer or more effective when compared to the OS remains unsettled. Therefore, to provide comprehensive information about the strategy of PCNL as well as OS in the treatment of staghorn renal stones, we performed this systematic review and meta-analysis of published studies comparing the efficacy and safety of PCNL and OS for surgical treatment of patients with staghorn renal stones. We hope it may guide urologists and patients to decide on the treatment modality, and to select the optimal treatment.

Materials and methods {#sec006}
=====================

A prospective protocol of objectives, literature-search strategy, inclusion and exclusion criteria, study selection, data extraction, outcome measurements, and methods of statistical analysis was prepared a priori according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis\[[@pone.0206810.ref016]\].

Search strategy {#sec007}
---------------

A comprehensive literature strategy search was performed by two members (Chen and Zhang) independently in Jan 2018. The PubMed, Embase, CNKI and the Cochrane Library databases were used to identify relevant studies up to Jan 2018. Separate searches were done with the following search terms: "'percutaneous nephrolithotomy' or 'PCNL' or 'PCN'" and "'Open surgery' or 'OS'" in combine with "'staghorn calculi' or 'staghorn renal stones'".

Inclusion and exclusion criteria {#sec008}
--------------------------------

The selected studies were included based on the following criteria: (1) studies reported comparison between PCNL and OS in patients with staghorn calculi; (2) the outcome measures consisted of at least two of the following things: complications, SFR, hospitalization times, operative times, blood loss, and blood transfusion. Exclusion criteria are as follows: (1) repeated publications or conference proceedings; (2) non-published materials, editorials or reviews; (3) studies containing patients with serious urinary infection, renal insufficiency, musculoskeletal deformities, solitary kidney or congenital abnormalities.

Study selection and data extraction {#sec009}
-----------------------------------

We screened the studies according to inclusion and exclusion criteria. Two authors (Feng and Yue) independently extracted data and appraised both quality and content. We contacted the authors of relevant studies to supplement incomplete data. Where disagreement arose, papers were re-examined and discussed, and the consensus was reached by the adjudicating senior authors (Zeng and Chen). The extracted data including: first author, year of publication, baseline patient characteristics, study period, study design, interventions, outcome measures, variations in PCNL techniques, statistical methods, and study conclusions. The outcomes included complications, SFR, hospitalization times, operative times, blood drop, and blood transfusion.

Quality assessment and statistical analysis {#sec010}
-------------------------------------------

The level of evidence (LE) of all included studies was assessed by the criteria provided by the Oxford Centre for Evidence-based Medicine\[[@pone.0206810.ref017]\]. And the quality of non-randomized controlled trials (non-RCTs) was assessed by Newcastle-Ottawa Scale.\[[@pone.0206810.ref018]\] The Cochrane risk of bias tool was applied to assess the methodological quality of RCTs.\[[@pone.0206810.ref019]\] All the meta-analyses were performed using Review Manager 5.2 software. The odds ratio (OR) and weighted mean difference (WMD) were used to compare dichotomous and continuous variables, respectively. All results were reported with 95% confidence intervals (CIs). Chi-square test and I-square test were used for testing heterogeneity between studies. If heterogeneity was not significant (*P* \> 0.10, *I*^*2*^ \< 50%), fixed-effect model was employed, otherwise, random-effect will be adopted. The results of the meta-analysis were expressed using forest graphs or tables. The Z-test determined the pooled effects, and *P* \< 0.05 was considered statistically significant. Subgroup analyses were performed to compare standard PCNL and mini-PCNL with OS. Funnel plots were used to screen for potential publication bias. Sensitivity analysis was undertaken using studies of high quality. Only outcomes with three or more than three studies were included in the sensitivity analysis.

Results {#sec011}
=======

The search strategy generated 790 studies. After an initial screening of title and abstract, 13 studies were thought to meet the inclusion criteria. After further screening of full text, we excluded 3 articles because of unavailable data. 10 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref015]\], which included 921 patients (531 cases for PCNL and 390 cases for OS) fulfilled the predefined inclusion criteria, and were included in the final analysis ([Fig 1](#pone.0206810.g001){ref-type="fig"}). Examination of the references listed for these studies and for the review articles did not yield any further studies for evaluation. [Table 1](#pone.0206810.t001){ref-type="table"} shows the baseline characteristics and quality assessment of all included studies. Among 10 included studies available for meta-analysis, 2 were prospective case-control studies\[[@pone.0206810.ref008],[@pone.0206810.ref015]\] (LE: 3b), 7 were retrospective case-control studies\[[@pone.0206810.ref006],[@pone.0206810.ref009]--[@pone.0206810.ref014]\] (LE: 3b) and 1 was RCT\[[@pone.0206810.ref007]\] (LE: 2b). The methodological qualities of included studies were relatively high for six of the nine non-randomized studies\[[@pone.0206810.ref006],[@pone.0206810.ref008]--[@pone.0206810.ref010],[@pone.0206810.ref014],[@pone.0206810.ref015]\] (NOS: 6 of 9 points), whereas three studies\[[@pone.0206810.ref011]--[@pone.0206810.ref013]\] were moderate quality with 5 scores. And the only one RCT\[[@pone.0206810.ref007]\] was high quality for 5 points (the Cochrane risk of bias tools: score from 0 to 7).

![Flow diagram of studies identified, included, and excluded.](pone.0206810.g001){#pone.0206810.g001}

10.1371/journal.pone.0206810.t001

###### The baseline characteristics and quality assessment of all included studies.

![](pone.0206810.t001){#pone.0206810.t001g}

  Study                      country   Study period   Study design   LE   Mean age ± SD (years)   Mean stone size   Gender(male/female)   cases, n          Study quality                     
  -------------------------- --------- -------------- -------------- ---- ----------------------- ----------------- --------------------- ----------------- --------------- ------- ---- ---- ----------------------------------------
  AL-KOHLANY KM et al 2005   Egypt     2001--2003     RCT            2b   48.6±8.5                48.7±10.9         18.7±6.9 cm^3^        18.8±8.1 cm^3^    17/26           23/22   43   45   5\#
  Aminsharifi A et al 2016   Iran      2010--2015     PCCS           3b   48±8.57                 48.21±7.87        79.06 ± 15.63 mm      77.0 ± 14.33 mm   13/3            11/3    16   14   7[\*](#t001fn002){ref-type="table-fn"}
  El-Nahas AR et al 2014     Egypt     2000--2013     RCCS           3b   7.1±2.93                7.6±3.31                                                                          28   28   6[\*](#t001fn002){ref-type="table-fn"}
  Falahatkar S et al 2009    Iran      2005--2006     PCCS           3b   46.5±13.4               46.04±13.6                                                35/37           19/29   72   48   6[\*](#t001fn002){ref-type="table-fn"}
  Zhang FBY et al 2017       Taiwan    2007--2013     RCCS           3b   54.3±411.6              50.5±11.1         19.8±5.6 cm^2^        19.7±6.4 cm^2^    21/40           3/8     61   11   7[\*](#t001fn002){ref-type="table-fn"}
  Cao GZ et al 2008          China     2003--2007     RCCS           3b   43.00±12.57             45.00±10.36       38.38 ±7.85cm         40.04 ±9.64cm     14/46           12/36   60   48   6[\*](#t001fn002){ref-type="table-fn"}
  Fei X et al 2012           China     2003--2011     RCCS           3b   46.5±14.5               42.3 ±10.5        3.7±1.6 cm^2^         3.5±1.4cm^2^                              54   48   5[\*](#t001fn002){ref-type="table-fn"}
  liang TS et al 2010        China     2003--2008     RCCS           3b   46.37±14.75             48.35±14.13       3.17±1.8cm            2.94±1.50cm       47/32           24/17   79   41   6[\*](#t001fn002){ref-type="table-fn"}
  Yang X et al 2014          China     2010--2012     RCCS           3b   45.1±3.2                43.6±3.8          37.9±2.5mm            36.7±2.6mm        26/20           25/15   46   40   5[\*](#t001fn002){ref-type="table-fn"}
  Zheng B et al 2011         China     2007--2010     RCCS           3b   45.56±10.23             44.32±11.11       41.01±7.30mm          42.34±6.96mm      39/33           39/31   72   70   5[\*](#t001fn002){ref-type="table-fn"}

LE = level of evidence, PCNL = Percutaneous nephrolithotomy, OS = open surgery, PCCS = prospective case controlled study, RCCS = retrospective case controlled study, RCT = randomized controlled trial.

\* Using Newcastle-Ottawa Scale (score from 0 to 9). \# Using The Cochrance collaboration\'s tool (score from 0 to 7).

Surgical technique for PCNL among all including studies varied in terms of image guidance, type of dilator, sheath size, type of lithotripsy, postoperative stent, and postoperative nephrostomy tube ([Table 2](#pone.0206810.t002){ref-type="table"}). In 4 studies\[[@pone.0206810.ref008],[@pone.0206810.ref009],[@pone.0206810.ref011],[@pone.0206810.ref015]\], percutaneous accesses were achieved under fluoroscopic guidance, 4 studies\[[@pone.0206810.ref006],[@pone.0206810.ref012]--[@pone.0206810.ref014]\] under ultrasound, 1 study\[[@pone.0206810.ref010]\] were combined fluoroscopic guidance with ultrasound and one study\[[@pone.0206810.ref007]\] was not recorded. Tract dilation was accomplished using Amplatz dilators in 7 studies\[[@pone.0206810.ref006],[@pone.0206810.ref008]--[@pone.0206810.ref011],[@pone.0206810.ref014],[@pone.0206810.ref015]\]. One studies\[[@pone.0206810.ref012]\] used Metal dilators. And one study\[[@pone.0206810.ref007]\] was not recorded. Three studies\[[@pone.0206810.ref010],[@pone.0206810.ref011],[@pone.0206810.ref014]\] were mini-PCNL with sheath sizes less than 24Fr, while 7 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref009],[@pone.0206810.ref012],[@pone.0206810.ref013],[@pone.0206810.ref015]\] were standard PCNL with sheath sizes greater than or equal to 24Fr. Fragmentation and stone removal was accomplished by pneumatic energy in 9 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref009],[@pone.0206810.ref011]--[@pone.0206810.ref015]\]. After completion of PNL, a nephrostomy tube was routinely placed in all including studies. A double-J stent was routinely placed in 5 studies\[[@pone.0206810.ref010]--[@pone.0206810.ref013],[@pone.0206810.ref015]\].

10.1371/journal.pone.0206810.t002

###### Variations in PCNL techniques, as stated in the methods section: An overview.
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  Studies                    Imaging   Dilator   sheath size(Fr)   Lithotripsy technique                            
  -------------------------- --------- --------- ----------------- ----------------------- ------- --- --- ---- --- -------
  AL-KOHLANY KM et al 2005                                                                 24      Y   Y            18
  Aminsharifi A et al 2016   F                                     Y                       30      Y                18
  El-Nahas AR et al 2014     F                                     Y                       24/30   Y                18
  Falahatkar S et al 2009    F                                     Y                       30      Y            Y   18
  Zhang FBY et al 2017       US                                    Y                       24      Y   Y            16
  Cao GZ et al 2008          F/US                                  Y                       18              Y    Y   14/16
  Fei X et al 2012           US                  24                Y                       Y               12       
  liang TS et al 2010        US                                    Y                       16/18   Y            Y   16/18
  Yang X et al 2014          US                  Y                                         24      Y   Y        Y   12
  Zheng B et al 2011         F                                     Y                       18      Y            Y   18

F = fluoroscopy, US = Ultrasound, NT = nephrostomy tube, US = ureteral stent, PCNL = Percutaneous nephrolithotomy, Y = yes

Primary outcomes {#sec012}
================

SFR {#sec013}
---

Four studies\[[@pone.0206810.ref006]--[@pone.0206810.ref008],[@pone.0206810.ref015]\] that assessed 310 patients reported on *immediate-SFR* ([Fig 2A](#pone.0206810.g002){ref-type="fig"}). PCNL provided a significantly lower immediate-SFR compared with OS (*OR*: 0.29; 95% *CI*: 0.16, 0.51; *P* \< 0.0001), with no significant between-study heterogeneity (*χ*^*2*^ = 6.08, *df* = 3, *p* = 0.11, *I*^*2*^ = 51%).

![Forest plot and meta-analysis of immediate SFR(a) and final SFR(b).](pone.0206810.g002){#pone.0206810.g002}

Data on *final SFR* were available in 9 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref014]\], which evaluated 804 patients([Fig 2B](#pone.0206810.g002){ref-type="fig"}). Meta-analysis of the 9 studies indicated that there was no significant difference between the two groups (*OR*: 1.17; 95% *CI*: 0.64, 2.15; *p* = 0.61), with significant between-study heterogeneity (*χ*^*2*^ = 14.47, *df* = 7, *P* = 0.04, *I*^*2*^ = 52%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results, with the pooled OR values of 0.92(95%*CI*: 0.43, 1.98; *P* = 0.83) and 1.71(95%*CI*: 0.7, 4.21; *P* = 0.24), respectively. However, the between-study heterogeneity was significantly reduced in subgroup analysis.

Complications {#sec014}
-------------

Nine studies\[[@pone.0206810.ref006]--[@pone.0206810.ref012],[@pone.0206810.ref014],[@pone.0206810.ref015]\] that assessed 822 patients reported on *overall complications* ([Fig 3C](#pone.0206810.g003){ref-type="fig"}). PCNL provided significantly lower overall complications compared with OS (*OR*: 0.59; 95% *CI*: 0.41, 0.84; *P* = 0.004), with no significant between-study heterogeneity (*χ*^*2*^ = 11.91, *df* = 8, *p* = 0.16, *I*^*2*^ = 33%). In subgroup analysis, the result of the subgroup of standard PCNL was consistent with the overall results, with the pooled OR values of 0.55(95%*CI*: 0.35, 0.85; *P* = 0.008), but with moderate between-study heterogeneity (*χ*^*2*^ = 9.48, *df* = 5, *p* = 0.09, *I*^*2*^ = 47%). However, there was no significant difference between mini-PCNL and OS (*OR*: 0.67; 95% *CI*: 0.36, 1.25; *p* = 0.21), with no between-study heterogeneity (*χ*^*2*^ = 2.2, *df* = 2, *P* = 0.33, *I*^*2*^ = 9%).

![Forest plot and meta-analysis of overall complications(c), minor complications(d) and major complications(e).](pone.0206810.g003){#pone.0206810.g003}

Data on *minor complications (Clavien I-II)* were available in 7 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref009],[@pone.0206810.ref011],[@pone.0206810.ref012],[@pone.0206810.ref014],[@pone.0206810.ref015]\], which evaluated 628 patients([Fig 3D](#pone.0206810.g003){ref-type="fig"}). Meta-analysis of the 7 studies indicated that there was no significant difference between the two groups (*OR*: 0.72; 95% *CI*: 0.47, 1.09; *p* = 0.12), with no between-study heterogeneity (*χ*^*2*^ = 5.5, *df* = 6, *P* = 0.48, *I*^*2*^ = 0%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results, with no between-study heterogeneity respectively.

Six studies\[[@pone.0206810.ref006],[@pone.0206810.ref007],[@pone.0206810.ref009],[@pone.0206810.ref011],[@pone.0206810.ref014],[@pone.0206810.ref015]\] reported *major complications(Clavien III-V)* ([Fig 3E](#pone.0206810.g003){ref-type="fig"}). There was no significant difference between the two groups (OR: 0.5; 95% CI: 0.23, 1.08; *P* = 0.08), with no between-study heterogeneity (*χ*^*2*^ = 3.25, *df* = 4, *P* = 0.52, *I*^*2*^ = 0%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results, with no between-study heterogeneity respectively.

Secondary outcomes {#sec015}
==================

Operative times {#sec016}
---------------

Nine studies\[[@pone.0206810.ref006]--[@pone.0206810.ref008],[@pone.0206810.ref010]--[@pone.0206810.ref015]\] assessed 868 patients and reported on *operative times* ([Fig 4F](#pone.0206810.g004){ref-type="fig"}) between the two groups favouring the PCNL(*WMD*: -59.01min; 95% *CI*: -81.09, -36.93; *p* \< 0.00001), with significant between-study heterogeneity (*χ*^*2*^ = 363.51, *df* = 8, *p* \< 0.00001, *I*^*2*^ = 98%). In subgroup analysis, the results of the subgroup of standard PCNL were consistent with the overall results, with significant between-study heterogeneity. However, there was no significant difference between mini-PCNL and OS (*WMD*: -25.02min; 95% *CI*: -61.27, 11.23; *p* \< 0.00001), with significant between-study heterogeneity.

![Forest plot and meta-analysis of operative times(f) and hospitalization times(g).](pone.0206810.g004){#pone.0206810.g004}

Hospitalization times {#sec017}
---------------------

Ten studies\[[@pone.0206810.ref006]--[@pone.0206810.ref015]\] assessed 924 patients and reported on *hospitalization times* ([Fig 4G](#pone.0206810.g004){ref-type="fig"}) between the two groups favouring the PCNL(*WMD*: -5.77d; 95% *CI*: -7.80, -3.74; *p* \< 0.00001), with significant between-study heterogeneity (*χ*^*2*^ = 439.01, *df* = 9, *p* \< 0.00001, *I*^*2*^ = 98%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results, with significant between-study heterogeneity respectively.

Blood loss {#sec018}
----------

Four studies\[[@pone.0206810.ref006],[@pone.0206810.ref012]--[@pone.0206810.ref014]\] assessed 380 patients and reported on *blood loss* ([Fig 5H](#pone.0206810.g005){ref-type="fig"}) between the two groups favouring the PCNL(*WMD*: -138.29*ml*; 95% *CI*: -244.98, -31.6; *p* = 0.01), with significant between-study heterogeneity (*χ*^*2*^ = 466.1, *df* = 3, *p* \< 0.00001, *I*^*2*^ = 99%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results, with no significant between-study heterogeneity.

![Forest plot and meta-analysis of blood loss(h) and blood transfusion(I).](pone.0206810.g005){#pone.0206810.g005}

Blood transfusion {#sec019}
-----------------

Data on *blood transfusion* were available in 8 studies\[[@pone.0206810.ref006]--[@pone.0206810.ref012],[@pone.0206810.ref015]\], which evaluated 702 patients([Fig 5I](#pone.0206810.g005){ref-type="fig"}). Meta-analysis indicated that PCNL provided less blood transfusion compared with OS (*OR*: 0.44; 95% *CI*: 0.29, 0.68; *P* = 0.00002), with no between-study heterogeneity (*χ*^*2*^ = 8.11, *df* = 7, *P* = 0.32, *I*^*2*^ = 14%). In subgroup analysis, the results of the subgroup of standard PCNL and mini-PCNL were consistent with the overall results.

Sensitivity analysis {#sec020}
--------------------

When high quality studies were assessed, no change in terms of the significance of each of the outcomes except for overall complications. Meta-analysis of 7 high quality studies\[[@pone.0206810.ref006]--[@pone.0206810.ref010],[@pone.0206810.ref014],[@pone.0206810.ref015]\] revealed that there was no significant difference between the two groups for surgical treatment of patients with staghorn stones, with no between-study heterogeneity. Between-study heterogeneity was significantly reduced by the sensitivity analysis for final SFR and blood loss. While heterogeneity remained statistically significant in operative times and hospitalization times. ([Table 3](#pone.0206810.t003){ref-type="table"})

10.1371/journal.pone.0206810.t003

###### Sensitivity analysis according to high quality studies comparing PCNL and OS.
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                          Number   patients   WMD/OR (95% CI)   p value   Study heterogeneity                                   
  ----------------------- -------- ---------- ----------------- --------- ----------------------- ----------- -------- --- ---- -----------
  Final SFR               6        287        187               474       0.8(0.34,1.91)          0.62        7.79     4   49   0.1
  Over complications      7        359        235               594       0.69(0.46,1.03)         0.07        8.51     6   29   0.2
  Minor complications     6        299        187               486       0.71(0.45,1.1)          0.13        5.47     5   9    0.36
  Major complications     5        283        173               456       0.73(0.31,1.74)         0.48        0.73     3   0    0.87
  Operative times         6        331        207               538       -55.56(-89.95,-21.17)   0.002       236.26   5   98   \<0.00001
  Hospitalization times   7        359        235               594       -4.46(-6.86,-2.06)      0.0003      231.7    6   97   \<0.00001
  Blood loss              2        140        52                192       -58.94(-66.19,-51.68)   \<0.00001   0.66     1   0    0.42
  Blood transfusion       6        280        194               474       0.55(0.35,0.88)         0.01        4.49     5   0    0.48

WMD = weighted mean difference, OR = odds ratio, 95% CI = 95% confidence interval

Publication bias outcomes {#sec021}
-------------------------

Funnel plots were conducted to assess the publication bias in this meta-analysis that reported overall complications ([Fig 6](#pone.0206810.g006){ref-type="fig"}). All studies lie inside the 95% CIs, with an even distribution around the vertical, indicating no obvious publication bias.

![Funnel plot for assessing publication bias (overall complications).](pone.0206810.g006){#pone.0206810.g006}

Discussion {#sec022}
==========

This meta-analysis of 10 studies, which included 921 patients from 1 RCT, 2 prospective case-control studies and 7 retrospective case-control studies, comparing the efficacy and safety of PCNL and OS for patients with staghorn stones. The pooled data showed that there was no significant difference in final-SFR between PCNL and OS, while PCNL provided a significantly lower immediate-SFR compared with OS. PCNL provided significantly lower overall complication rate compared with OS. However, no significant differences were found in minor complications (Clavien I-II) and major complications (Clavien III-V). PCNL provided significantly shorter operative times and hospitalization times compared with OS. And PCNL provided significantly less blood loss and blood transfusion compared with OS. In subgroup analysis, there was no significant difference for overall complications and operative times between mini-PCNL and OS. In sensitivity analysis, there was no significant difference for overall complications between PCNL and OS.

In the application of urolithiasis surgery, SFR represents a paramount important parameter. Al-Kohlany KM et al.\[[@pone.0206810.ref007]\] also found that both PCNL and OS were comparable in regard to SFRs at discharge home and at follow-up. However, Zhang FBY et al.\[[@pone.0206810.ref006]\] found that OS provided a significantly higher final SFR compared with PCNL (97.5% vs 76.1, *p* \< 0.001). Our pooled data showed that although OS provided a significantly higher immediate-SFR compared with PCNL, no significant difference was found in final-SFR. And the results of the subgroup and sensitivity analysis of standard PCNL and mini-PCNL were consistent with the overall results.

The safety of the patients is also an important parameter. Our pooled data showed that PCNL provided significantly lower overall complication rate compared with OS. And no significant differences were found in minor complications (Clavien I-II) and major complications (Clavien III-V). However, there was no significant difference for overall complications in subgroup analysis between mini-PCNL and OS. And no significant difference was found for overall complications between PCNL and OS in sensitivity analysis. Our pooled data also found that although PCNL provided significantly shorter operative times compared with OS, no significant difference was found for operative times between mini-PCNL and OS in subgroup analysis. The disadvantage of small instruments is that it is necessary to fragment staghorn stones into smaller pieces that fit through the narrower sheaths, which would increase the operative times of the mini-PCNL. Prolonged operating times lead the trend towards higher complications for mini-PCNL compared with standard PCNL.

A great deal of studies\[[@pone.0206810.ref012]--[@pone.0206810.ref014]\] found that PCNL provided significantly less blood loss compared with OS. While Zhang FBY et al.\[[@pone.0206810.ref006]\] found that OS provided less blood loss compared with OS, though with no statistically significant. However, our pooled data showed that PCNL provided significantly less blood loss and blood transfusion compared with OS. And the results of the subgroup and sensitivity analysis of standard PCNL and mini-PCNL were consistent with the overall results.

Several limitations of our meta-analysis should be taken into consideration when interpreting the results. First of all, nine of ten studies were non-RCTs. Those results should be interpreted with caution given the potential for selection and treatment bias due to the non-RCT heterogeneous nature. Heterogeneity among studies were found to be high for several parameters, including final SFR, operative times, hospitalization times, and blood loss. Although between-study heterogeneity was significantly reduced by the sensitivity analysis for final SFR and blood loss, heterogeneity of operative times and hospitalization times remained statistically significant. The differences in surgical technique and surgical experience, and outcome definitions have all acted an important role in the heterogeneity. The surgical technique for PCNL and OS, the diameters and location of stones were not similar across the different studies. Overall, only 10 studies with 921 patients could be included in the meta-analysis. Such a small number of studies were unable to make strong conclusion. Thus, further large sample prospective, multi-centric studies and RCTs should be undertaken to confirm our findings.

Nevertheless, our meta-analysis was conducted at an appropriate time. Ten data have accumulated for analysis. We applied multiple strategies to identify studies, strict criteria to include and evaluate the methodological quality of the studies, and subgroup analysis to minimize the heterogeneity. Hence, we provide the most up-to-date information in surgical treatment of patients with staghorn calculi, and this could guide urologists and patients to decide on the surgical method, and to select the optimal therapy.

Conclusion {#sec023}
==========

Our systematic review and meta-analysis demonstrated that standard PCNL seems to be a safe and feasible alternative compared to OS or mini-PCNL for patients with staghorn stones with many advantages, such as shorter hospitalization times and operative times, less blood loss and blood transfusion, and without increasing complications nor decreasing final SFR. However, our conclusion should be treated prudently and further large sample prospective, multi-centric studies and randomized control trials should be undertaken to confirm our findings.
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PCNL

:   Percutaneous Nephrolithotomy

OS

:   open surgery

WMD

:   Weighted mean difference

OR

:   Odds ratio

95%CI

:   95% confidence interval

LE

:   Level of evidence

RCT

:   Randomized controlled trial

SFR

:   stones free rate
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